Pricing Log in Create free account

AnaptysBio, Inc. (ANAB) vs KARDIGAN INC (KARD)

AnaptysBio, Inc. and KARDIGAN INC are both Biotechnology companies. AnaptysBio, Inc. and KARDIGAN INC are of similar size ($1.4B and $1.3B). KARDIGAN INC has the higher net margin (0.00% vs −11.5%) and the lower return on invested capital (−908.8% vs 0.00%). Across the 13 metrics below, AnaptysBio, Inc. leads on 7 and KARDIGAN INC on 6.

Valuation

Metric ANAB KARD Biotechnology median
P/E n/m n/m 10.60
P/S 5.73 n/m 9.40
P/B 104.50 0.63 2.13
Price to free cash flow 302.14 n/m 25.18
EV/EBITDA 26.10 0.82 0.66
EV/Sales 4.51 n/m 9.02
Earnings yield (1.83%) (95.11%) (32.88%)
Free cash flow yield 0.33% (43.18%) (23.13%)

Profitability

Metric ANAB KARD Biotechnology median
Gross margin 100.00% — 68.51%
Operating margin 17.56% 0.00% 0.00%
Net margin (11.53%) 0.00% 0.00%
Free cash flow margin 1.90% 0.00% 0.00%
Return on equity (114.55%) 0.00% (51.96%)
Return on assets (7.13%) 0.00% (46.06%)
Return on invested capital 0.00% (908.80%) 0.00%

Growth

Metric ANAB KARD Biotechnology median
Revenue growth (TTM) 107.73% — 6.76%
EPS growth (last fiscal year) 91.02% (68.79%) 29.88%
Revenue growth, 5-year CAGR 25.62% — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ANAB KARD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.58 8.72 4.97
Net debt to EBITDA (6.84) 1.70 1.01

Dividend

Metric ANAB KARD Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ANAB KARD Biotechnology median
Market cap 1.36b 1.30b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack